JP2022511495A5 - - Google Patents

Info

Publication number
JP2022511495A5
JP2022511495A5 JP2021531796A JP2021531796A JP2022511495A5 JP 2022511495 A5 JP2022511495 A5 JP 2022511495A5 JP 2021531796 A JP2021531796 A JP 2021531796A JP 2021531796 A JP2021531796 A JP 2021531796A JP 2022511495 A5 JP2022511495 A5 JP 2022511495A5
Authority
JP
Japan
Prior art keywords
compound
cancer
crystalline form
degrees
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531796A
Other languages
English (en)
Japanese (ja)
Other versions
JP7649241B2 (ja
JP2022511495A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/083773 external-priority patent/WO2020115183A1/en
Publication of JP2022511495A publication Critical patent/JP2022511495A/ja
Publication of JP2022511495A5 publication Critical patent/JP2022511495A5/ja
Application granted granted Critical
Publication of JP7649241B2 publication Critical patent/JP7649241B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531796A 2018-12-06 2019-12-05 Ｍｃｌ－１阻害剤の新しい結晶形、その調製プロセス及びそれらを含有する医薬組成物 Active JP7649241B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306634.9 2018-12-06
EP18306634 2018-12-06
PCT/EP2019/083773 WO2020115183A1 (en) 2018-12-06 2019-12-05 New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them.

Publications (3)

Publication Number Publication Date
JP2022511495A JP2022511495A (ja) 2022-01-31
JP2022511495A5 true JP2022511495A5 (https=) 2022-11-22
JP7649241B2 JP7649241B2 (ja) 2025-03-19

Family

ID=64665802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531796A Active JP7649241B2 (ja) 2018-12-06 2019-12-05 Ｍｃｌ－１阻害剤の新しい結晶形、その調製プロセス及びそれらを含有する医薬組成物

Country Status (26)

Country Link
US (2) US12129261B2 (https=)
EP (1) EP3891156B1 (https=)
JP (1) JP7649241B2 (https=)
KR (1) KR102855345B1 (https=)
CN (1) CN113166169A (https=)
AR (1) AR117255A1 (https=)
AU (1) AU2019391329B2 (https=)
BR (1) BR112021010072A2 (https=)
CA (1) CA3121363A1 (https=)
DK (1) DK3891156T3 (https=)
EA (1) EA202191534A1 (https=)
ES (1) ES2971258T3 (https=)
FI (1) FI3891156T3 (https=)
HR (1) HRP20240211T1 (https=)
HU (1) HUE065266T2 (https=)
IL (1) IL283656B2 (https=)
LT (1) LT3891156T (https=)
MA (1) MA54379B1 (https=)
MD (1) MD3891156T2 (https=)
MX (1) MX2021006702A (https=)
PL (1) PL3891156T3 (https=)
PT (1) PT3891156T (https=)
RS (1) RS65047B1 (https=)
SI (1) SI3891156T1 (https=)
TW (1) TWI905090B (https=)
WO (1) WO2020115183A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Similar Documents

Publication Publication Date Title
JP6537601B2 (ja) アザ二環式化合物の結晶
KR102142796B1 (ko) 피리디닐아미노피리미딘 유도체의 염, 그의 제조 방법, 및 그의 용도
JP2020528907A5 (https=)
KR102061917B1 (ko) 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
JP2020511467A5 (https=)
JP2012153722A5 (https=)
JP2020517611A5 (https=)
JP2007521340A5 (https=)
JP2024534014A5 (https=)
CN110590749B (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
TW201736383A (zh) 2-[(2s)-1-氮雜雙環[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物之晶形
JP2014524476A5 (https=)
JP2020521732A5 (https=)
JP2022511495A5 (https=)
FI3317264T3 (fi) (S)-[3,4-difluori-2-(2-fluori-4-jodifenyyliamino)fenyyli][3-hydroksi-3-(piperidin-2-yyli)atsetidin-1-yyli]metanonin kiteinen fumaraattisuola
JP2018521969A (ja) 医薬用共結晶及びその用途
HRP20240211T1 (hr) Novi kristalni oblici tienopirimidina kao mcl-1 inhibitora
WO2017020869A1 (zh) 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺的晶型b及其制备方法和应用
CN115551860B (zh) 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
TWI535724B (zh) 埃克替尼磷酸鹽的新晶型及其用途
RU2021119029A (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
KR20230074785A (ko) 아릴아미노퀴나졸린 함유 화합물의 염, 이의 제조 방법 및 적용
NZ776907B2 (en) New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them.
JP2023531078A (ja) 化合物の結晶形態
RU2023135057A (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции